Free Newsletter
Roche, Teva square off in patent fight
To brand-name drug makers, Teva Pharmaceuticals is something of a Big Bad Wolf: I'll huff and I'll puff and I'll blow your patents down!
Of course, Big Pharma is no defenseless little pig--just witness Novartis' successful (at least for now) shutdown of Teva's copycat Famvir. Now, Roche is suing Teva for producing a generic version of its osteoporosis treatment Boniva, whose patents begin to expire in 2012. The drug racked up $314 million in sales just in the first half of 2007, so it's well worth the legal expense. Roche is asking a New Jersey court to keep Teva's generic version off the U.S. market.
- read the article from the International Herald Tribune
Related Articles:
Novartis wins round on Famvir knockoff. Report
Injectable Boniva approved. Report
Researchers tout once-monthly Boniva data. Report
Roche, GSK outline head-to-head trial of Boniva, Fosamax. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: